Aminocaproic acid (injection): Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Aminocaproic acid}} | ||
{{CMG}} | {{CMG}} | ||
'''''For patient information, click <u>[[ | '''''For patient information, click <u>[[Aminocaproic acid (patient information)|here]]'''''</u>. | ||
==Overview== | ==Overview== | ||
'''Aminocaproic acid''' (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the [[amino acid]][[lysine]], which makes it an effective [[enzyme inhibitor|inhibitor]] for [[enzyme|enzymes]] which bind that particular residue. Such enzymes include[[proteolytic]] enzymes (which break down [[protein|proteins]]) including [[plasminogen]], the enzyme responsible for [[fibrinolysis]]. For this reason it is effective in treatment of some [[coagulopathy|bleeding disorders]] and is marketed as Amicar. | '''Aminocaproic acid''' (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the [[amino acid]][[lysine]], which makes it an effective [[enzyme inhibitor|inhibitor]] for [[enzyme|enzymes]] which bind that particular residue. Such enzymes include[[proteolytic]] enzymes (which break down [[protein|proteins]]) including [[plasminogen]], the enzyme responsible for [[fibrinolysis]]. For this reason it is effective in treatment of some [[coagulopathy|bleeding disorders]] and is marketed as Amicar. | ||
==Category== | ==Category== | ||
| Line 20: | Line 19: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' [[ | ''' [[Aminocaproic acid indications and usage|Indications and Usage]]''' | ||
'''| [[ | '''| [[Aminocaproic acid dosage and administration|Dosage and Administration]]''' | ||
'''| [[ | '''| [[Aminocaproic acid dosage forms and strengths|Dosage Forms and Strengths]]''' | ||
'''| [[ | '''| [[Aminocaproic acid contraindications|Contraindications]]''' | ||
'''| [[ | '''| [[Aminocaproic acid warnings|Warnings and Precautions]]''' | ||
'''| [[ | '''| [[Aminocaproic acid adverse reactions|Adverse Reactions]]''' | ||
'''| [[ | '''| [[Aminocaproic acid drug interactions|Drug Interactions]]''' | ||
'''| [[ | '''| [[Aminocaproic acid use in specific populations|Use in Specific Populations]]''' | ||
'''| [[ | '''| [[Aminocaproic acid overdosage|Overdosage]]''' | ||
'''| [[ | '''| [[Aminocaproic acid description|Description]]''' | ||
'''| [[ | '''| [[Aminocaproic acid clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[ | '''| [[Aminocaproic acid nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[ | '''| [[Aminocaproic acid clinical studies|Clinical Studies]]''' | ||
'''| [[ | '''| [[Aminocaproic acid how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[ | '''| [[Aminocaproic acid patient counseling information|Patient Counseling Information]]''' | ||
'''| [[ | '''| [[Aminocaproic acid labels and packages|Labels and Packages]]''' | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine [[analogue]], it binds reversibly to the [[kringle domain]] of the enzyme [[plasminogen]] and blocks binding of [[fibrin]], which is normally activated to [[plasmin]]. | Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine [[analogue]], it binds reversibly to the [[kringle domain]] of the enzyme [[plasminogen]] and blocks binding of [[fibrin]], which is normally activated to [[plasmin]]. | ||
| Line 54: | Line 52: | ||
[[ja:Ε-アミノカプロン酸]] | [[ja:Ε-アミノカプロン酸]] | ||
[[pl:Kwas ε-aminokapronowy]] | [[pl:Kwas ε-aminokapronowy]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 21:46, 29 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here.
Overview
Aminocaproic acid (also known as Amicar, є-amino caproic acid, or 6-aminohexanoic acid) is a derivative and analogue of the amino acidlysine, which makes it an effective inhibitor for enzymes which bind that particular residue. Such enzymes includeproteolytic enzymes (which break down proteins) including plasminogen, the enzyme responsible for fibrinolysis. For this reason it is effective in treatment of some bleeding disorders and is marketed as Amicar.
Category
Antifibrinolytics
US Brand Names
AMICAR®
FDA Package Insert
Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
Aminocaproic acid works as an anti-fibrinolytic or anti-proteolytic. As a lysine analogue, it binds reversibly to the kringle domain of the enzyme plasminogen and blocks binding of fibrin, which is normally activated to plasmin.